A carregar...
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
Inhibition of PCSK9 is a novel therapeutic strategy aimed at reducing low-density-lipoprotein cholesterol (LDL-C) and cardiovascular risk. Evolocumab is a fully humanized monoclonal antibody that inhibits PCSK9, an enzyme that binds to LDL receptors and prevents them from recycling to the hepatocyte...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513834/ https://ncbi.nlm.nih.gov/pubmed/28744103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S114091 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|